CSU announced Wednesday that it had received a $25.2 million,
seven-year contract from the National Institutes of Health to
further its research in the battle against tuberculosis, a
bacterial lung infection that causes 3 million deaths annually.
CSU’s Mycobacteria Research Laboratories of the College of
Veterinary Medicine and Biomedical Sciences received the NIH
contract to research drugs and vaccines that fight tuberculosis.
The contract will also help scientists accumulate tuberculosis
research materials to help other researchers around the world
advance their work as well.
John Belisle, director of the Mycobacteria Research Laboratories
and principal investigator for the NIH contract, said the grant is
a continuation of a successful and ongoing program.
“Our main focus is to identify products made by bacteria that
are involved in the disease process. We will also develop vaccines,
drugs or diagnostics and accelerate the overall vaccine development
supported by NIH,” Belisle said.
Belisle will be working on a team with several other scientists,
including Angelo Izzo, one of the two primary co-principal
“I feel good that we are able to advance the area of
tuberculosis vaccines farther. My involvement is to direct the
vaccine testing components of the contract and to oversee
experiments when candidates of tuberculosis are submitted to
contracts,” Izzo said.
Another research investigator on the NIH contract is Richard
Slayden, who is responsible for the post-genomic technology
“The NIH contract allows us to put necessary effort into
tuberculosis treatment,” Slayden said.
In addition to receiving the contract from NIH this year, the
Mycobacteria Research Laboratories was awarded a five-year, $3
million NIH grant last year that is being used to conduct studies
examining the long-term safety and effectiveness of tuberculosis
CSU administration members were honored to receive this
recognition from NIH.
“There are very few of these contracts awarded,” said Anthony
Frank, vice president for research and information technology at
CSU. “When an institution receives a contact, NIH views the faculty
and scientists as top-notch.”